메뉴 건너뛰기




Volumn 25, Issue 6, 2011, Pages 279-290

Managing resistance in chronic myeloid leukemia

Author keywords

Bcr Abl; Chronic myeloid leukemia; Imatinib; Tyrosine Kinase Inhibitor

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; ALISERTIB; ASH 2008; AURORA KINASE INHIBITOR; BAFETINIB; BCR ABL PROTEIN; BOSUTINIB; DANUSERTIB; DASATINIB; DC 2036; DCC 2036; DOXORUBICIN; HOMOHARRINGTONINE; IMATINIB; INTERFERON; KW 2449; NILOTINIB; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR; TOZASERTIB; UNCLASSIFIED DRUG; VORINOSTAT; XL 228;

EID: 80055023013     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2011.09.001     Document Type: Article
Times cited : (55)

References (140)
  • 2
    • 0035934067 scopus 로고    scopus 로고
    • Chronic myelogenous leukemia
    • Kalidas M., Kantarjian H., Talpaz M. Chronic myelogenous leukemia. JAMA 2001, 286:895-898.
    • (2001) JAMA , vol.286 , pp. 895-898
    • Kalidas, M.1    Kantarjian, H.2    Talpaz, M.3
  • 3
    • 0022352068 scopus 로고
    • Evidence of a new chimeric bcr/c-abl mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromosome
    • Stam K., Heisterkamp N., Grosveld G., de Klein A., Verma R.S., Coleman M., et al. Evidence of a new chimeric bcr/c-abl mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromosome. N Engl J Med 1985, 313:1429-1433.
    • (1985) N Engl J Med , vol.313 , pp. 1429-1433
    • Stam, K.1    Heisterkamp, N.2    Grosveld, G.3    de Klein, A.4    Verma, R.S.5    Coleman, M.6
  • 4
    • 0021346853 scopus 로고
    • Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22
    • Groffen J., Stephenson J.R., Heisterkamp N., de Klein A., Bartram C.R., Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984, 36:93-99.
    • (1984) Cell , vol.36 , pp. 93-99
    • Groffen, J.1    Stephenson, J.R.2    Heisterkamp, N.3    de Klein, A.4    Bartram, C.R.5    Grosveld, G.6
  • 5
    • 0000286732 scopus 로고
    • A minute chromosome in human chronic granulocytic leukemia (abstract)
    • Nowell P.C., Hungerford D. A minute chromosome in human chronic granulocytic leukemia (abstract). Science 1960, 132:1497.
    • (1960) Science , vol.132 , pp. 1497
    • Nowell, P.C.1    Hungerford, D.2
  • 6
    • 0015694748 scopus 로고
    • Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining
    • Rowley J.D. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973, 243:290-293.
    • (1973) Nature , vol.243 , pp. 290-293
    • Rowley, J.D.1
  • 7
    • 0029947186 scopus 로고    scopus 로고
    • Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
    • Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996, 2:561-566.
    • (1996) Nat Med , vol.2 , pp. 561-566
    • Druker, B.J.1    Tamura, S.2    Buchdunger, E.3    Ohno, S.4    Segal, G.M.5    Fanning, S.6
  • 8
    • 0035810147 scopus 로고    scopus 로고
    • Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
    • Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344:1031-1037.
    • (2001) N Engl J Med , vol.344 , pp. 1031-1037
    • Druker, B.J.1    Talpaz, M.2    Resta, D.J.3    Peng, B.4    Buchdunger, E.5    Ford, J.M.6
  • 9
    • 0037085785 scopus 로고    scopus 로고
    • Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study
    • Talpaz M., Silver R.T., Druker B.J., Goldman J.M., Gambacorti-Passerini C., Guilhot F., et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002, 99:1928-1937.
    • (2002) Blood , vol.99 , pp. 1928-1937
    • Talpaz, M.1    Silver, R.T.2    Druker, B.J.3    Goldman, J.M.4    Gambacorti-Passerini, C.5    Guilhot, F.6
  • 10
    • 10744233716 scopus 로고    scopus 로고
    • Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
    • O'Brien S.G., Guilhot F., Larson R.A., Gathmann I., Baccarani M., Cervantes F., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348:994-1004.
    • (2003) N Engl J Med , vol.348 , pp. 994-1004
    • O'Brien, S.G.1    Guilhot, F.2    Larson, R.A.3    Gathmann, I.4    Baccarani, M.5    Cervantes, F.6
  • 13
    • 77949767505 scopus 로고    scopus 로고
    • International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib
    • Deininger M., O'Brien S.G., Guilhot F., Goldman J.M., Hochhaus A., Hughes T.P., et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. ASH Annual Meeting Abstracts 2009, 114:1126-
    • (2009) ASH Annual Meeting Abstracts , vol.114
    • Deininger, M.1    O'Brien, S.G.2    Guilhot, F.3    Goldman, J.M.4    Hochhaus, A.5    Hughes, T.P.6
  • 14
    • 49149111543 scopus 로고    scopus 로고
    • Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis
    • de Lavallade H., Apperley J.F., Khorashad J.S., Milojkovic D., Reid A.G., Bua M., et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008, 26:3358-3363.
    • (2008) J Clin Oncol , vol.26 , pp. 3358-3363
    • de Lavallade, H.1    Apperley, J.F.2    Khorashad, J.S.3    Milojkovic, D.4    Reid, A.G.5    Bua, M.6
  • 15
    • 54049130762 scopus 로고    scopus 로고
    • A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials
    • Lucas C.M., Wang L., Austin G.M., Knight K., Watmough S.J., Shwe K.H., et al. A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Leukemia 2008, 22:1963-1966.
    • (2008) Leukemia , vol.22 , pp. 1963-1966
    • Lucas, C.M.1    Wang, L.2    Austin, G.M.3    Knight, K.4    Watmough, S.J.5    Shwe, K.H.6
  • 16
    • 25444488489 scopus 로고    scopus 로고
    • Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia
    • Barnes D.J., Palaiologou D., Panousopoulou E., Schultheis B., Yong A.S.M., Wong A., et al. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res 2005, 65:8912-8919.
    • (2005) Cancer Res , vol.65 , pp. 8912-8919
    • Barnes, D.J.1    Palaiologou, D.2    Panousopoulou, E.3    Schultheis, B.4    Yong, A.S.M.5    Wong, A.6
  • 17
    • 0035800507 scopus 로고    scopus 로고
    • Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
    • Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293:876-880.
    • (2001) Science , vol.293 , pp. 876-880
    • Gorre, M.E.1    Mohammed, M.2    Ellwood, K.3    Hsu, N.4    Paquette, R.5    Rao, P.N.6
  • 18
    • 0001686739 scopus 로고    scopus 로고
    • Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
    • Shah N.P., Nicoll J.M., Nagar B., Gorre M.E., Paquette R.L., Kuriyan J., et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002, 2:117-125.
    • (2002) Cancer Cell , vol.2 , pp. 117-125
    • Shah, N.P.1    Nicoll, J.M.2    Nagar, B.3    Gorre, M.E.4    Paquette, R.L.5    Kuriyan, J.6
  • 19
    • 33847191776 scopus 로고    scopus 로고
    • Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib
    • Sherbenou D.W., Wong M.J., Humayun A., McGreevey L.S., Harrell P., Yang R., et al. Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib. Leukemia 2007, 21:489-493.
    • (2007) Leukemia , vol.21 , pp. 489-493
    • Sherbenou, D.W.1    Wong, M.J.2    Humayun, A.3    McGreevey, L.S.4    Harrell, P.5    Yang, R.6
  • 20
    • 33745102555 scopus 로고    scopus 로고
    • Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
    • Talpaz M., Shah N.P., Kantarjian H., Donato N., Nicoll J., Paquette R., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006, 354:2531-2541.
    • (2006) N Engl J Med , vol.354 , pp. 2531-2541
    • Talpaz, M.1    Shah, N.P.2    Kantarjian, H.3    Donato, N.4    Nicoll, J.5    Paquette, R.6
  • 21
    • 9444282642 scopus 로고    scopus 로고
    • Active transport of imatinib into and out of cells: implications for drug resistance
    • Thomas J., Wang L., Clark R.E., Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004, 104:3739-3745.
    • (2004) Blood , vol.104 , pp. 3739-3745
    • Thomas, J.1    Wang, L.2    Clark, R.E.3    Pirmohamed, M.4
  • 22
  • 23
    • 34548825795 scopus 로고    scopus 로고
    • Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia
    • O'Hare T., Eide C.A., Deininger M.W. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007, 110:2242-2249.
    • (2007) Blood , vol.110 , pp. 2242-2249
    • O'Hare, T.1    Eide, C.A.2    Deininger, M.W.3
  • 24
    • 33846228789 scopus 로고    scopus 로고
    • Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia
    • Soverini S., Colarossi S., Gnani A., Rosti G., Castagnetti F., Poerio A., et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 2006, 12:7374-7379.
    • (2006) Clin Cancer Res , vol.12 , pp. 7374-7379
    • Soverini, S.1    Colarossi, S.2    Gnani, A.3    Rosti, G.4    Castagnetti, F.5    Poerio, A.6
  • 25
    • 23044458596 scopus 로고    scopus 로고
    • ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia
    • Soverini S., Martinelli G., Rosti G., Bassi S., Amabile M., Poerio A., et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005, 23:4100-4109.
    • (2005) J Clin Oncol , vol.23 , pp. 4100-4109
    • Soverini, S.1    Martinelli, G.2    Rosti, G.3    Bassi, S.4    Amabile, M.5    Poerio, A.6
  • 26
    • 10744232328 scopus 로고    scopus 로고
    • Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis
    • Branford S., Rudzki Z., Walsh S., Parkinson I., Grigg A., Szer J., et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003, 102:276-283.
    • (2003) Blood , vol.102 , pp. 276-283
    • Branford, S.1    Rudzki, Z.2    Walsh, S.3    Parkinson, I.4    Grigg, A.5    Szer, J.6
  • 27
    • 73949105873 scopus 로고    scopus 로고
    • Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations
    • Muller M.C., Cortes J.E., Kim D.-W., Druker B.J., Erben P., Pasquini R., et al. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood 2009, 114:4944-4953.
    • (2009) Blood , vol.114 , pp. 4944-4953
    • Muller, M.C.1    Cortes, J.E.2    Kim, D.-W.3    Druker, B.J.4    Erben, P.5    Pasquini, R.6
  • 28
    • 54349089682 scopus 로고    scopus 로고
    • Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression
    • Khorashad J.S., de Lavallade H., Apperley J.F., Milojkovic D., Reid A.G., Bua M., et al. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol 2008, 26:4806-4813.
    • (2008) J Clin Oncol , vol.26 , pp. 4806-4813
    • Khorashad, J.S.1    de Lavallade, H.2    Apperley, J.F.3    Milojkovic, D.4    Reid, A.G.5    Bua, M.6
  • 29
    • 34848911943 scopus 로고    scopus 로고
    • Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency
    • Shah N.P., Skaggs B.J., Branford S., Hughes T.P., Nicoll J.M., Paquette R.L., et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 2007, 117:2562-2569.
    • (2007) J Clin Invest , vol.117 , pp. 2562-2569
    • Shah, N.P.1    Skaggs, B.J.2    Branford, S.3    Hughes, T.P.4    Nicoll, J.M.5    Paquette, R.L.6
  • 30
    • 76249090055 scopus 로고    scopus 로고
    • Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?
    • Branford S., Melo J.V., Hughes T.P. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?. Blood 2009, 114:5426-5435.
    • (2009) Blood , vol.114 , pp. 5426-5435
    • Branford, S.1    Melo, J.V.2    Hughes, T.P.3
  • 31
    • 9444264703 scopus 로고    scopus 로고
    • BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks
    • Nowicki M.O., Falinski R., Koptyra M., Slupianek A., Stoklosa T., Gloc E., et al. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood 2004, 104:3746-3753.
    • (2004) Blood , vol.104 , pp. 3746-3753
    • Nowicki, M.O.1    Falinski, R.2    Koptyra, M.3    Slupianek, A.4    Stoklosa, T.5    Gloc, E.6
  • 33
    • 0141816691 scopus 로고    scopus 로고
    • P210 BCR/ABL kinase regulates nucleotide excision repair (NER) and resistance to UV radiation
    • Canitrot Y., Falinski R., Louat T., Laurent G., Cazaux C., Hoffmann J.S., et al. p210 BCR/ABL kinase regulates nucleotide excision repair (NER) and resistance to UV radiation. Blood 2003, 102:2632-2637.
    • (2003) Blood , vol.102 , pp. 2632-2637
    • Canitrot, Y.1    Falinski, R.2    Louat, T.3    Laurent, G.4    Cazaux, C.5    Hoffmann, J.S.6
  • 34
    • 70349251859 scopus 로고    scopus 로고
    • BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair
    • Fernandes M.S., Reddy M.M., Gonneville J.R., DeRoo S.C., Podar K., Griffin J.D., et al. BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair. Blood 2009, 114:1813-1819.
    • (2009) Blood , vol.114 , pp. 1813-1819
    • Fernandes, M.S.1    Reddy, M.M.2    Gonneville, J.R.3    DeRoo, S.C.4    Podar, K.5    Griffin, J.D.6
  • 35
    • 43249083718 scopus 로고    scopus 로고
    • Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study
    • Larson R.A., Druker B.J., Guilhot F., O'Brien S.G., Riviere G.J., Krahnke T., et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008, 111:4022-4028.
    • (2008) Blood , vol.111 , pp. 4022-4028
    • Larson, R.A.1    Druker, B.J.2    Guilhot, F.3    O'Brien, S.G.4    Riviere, G.J.5    Krahnke, T.6
  • 36
    • 67049087117 scopus 로고    scopus 로고
    • Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study
    • Noens L., van Lierde M.A., De Bock R., Verhoef G., Zachee P., Berneman Z., et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009, 113:5401-5411.
    • (2009) Blood , vol.113 , pp. 5401-5411
    • Noens, L.1    van Lierde, M.A.2    De Bock, R.3    Verhoef, G.4    Zachee, P.5    Berneman, Z.6
  • 37
    • 77952467377 scopus 로고    scopus 로고
    • Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib
    • Marin D., Bazeos A., Mahon F.X., Eliasson L., Milojkovic D., Bua M., et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010, 28:2381-2388.
    • (2010) J Clin Oncol , vol.28 , pp. 2381-2388
    • Marin, D.1    Bazeos, A.2    Mahon, F.X.3    Eliasson, L.4    Milojkovic, D.5    Bua, M.6
  • 38
    • 77953934202 scopus 로고    scopus 로고
    • CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity
    • Green H., Skoglund K., Rommel F., Mirghani R.A., Lotfi K. CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity. Eur J Clin Pharmacol 2010, 66:383-386.
    • (2010) Eur J Clin Pharmacol , vol.66 , pp. 383-386
    • Green, H.1    Skoglund, K.2    Rommel, F.3    Mirghani, R.A.4    Lotfi, K.5
  • 40
    • 0042305479 scopus 로고    scopus 로고
    • Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients
    • Gambacorti-Passerini C., Zucchetti M., Russo D., Frapolli R., Verga M., Bungaro S., et al. Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 2003, 9:625-632.
    • (2003) Clin Cancer Res , vol.9 , pp. 625-632
    • Gambacorti-Passerini, C.1    Zucchetti, M.2    Russo, D.3    Frapolli, R.4    Verga, M.5    Bungaro, S.6
  • 41
    • 10744232038 scopus 로고    scopus 로고
    • Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivo
    • Larghero J., Leguay T., Mourah S., Madelaine-Chambrin I., Taksin A.L., Raffoux E., et al. Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivo. Biochem Pharmacol 2003, 66:1907-1913.
    • (2003) Biochem Pharmacol , vol.66 , pp. 1907-1913
    • Larghero, J.1    Leguay, T.2    Mourah, S.3    Madelaine-Chambrin, I.4    Taksin, A.L.5    Raffoux, E.6
  • 42
    • 33750735723 scopus 로고    scopus 로고
    • Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors
    • Delbaldo C., Chatelut E., Re M., Deroussent A., Seronie-Vivien S., Jambu A., et al. Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res 2006, 12:6073-6078.
    • (2006) Clin Cancer Res , vol.12 , pp. 6073-6078
    • Delbaldo, C.1    Chatelut, E.2    Re, M.3    Deroussent, A.4    Seronie-Vivien, S.5    Jambu, A.6
  • 43
    • 0034684075 scopus 로고    scopus 로고
    • Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571
    • Gambacorti-Passerini C., Barni R., le Coutre P., Zucchetti M., Cabrita G., Cleris L., et al. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 2000, 92:1641-1650.
    • (2000) J Natl Cancer Inst , vol.92 , pp. 1641-1650
    • Gambacorti-Passerini, C.1    Barni, R.2    le Coutre, P.3    Zucchetti, M.4    Cabrita, G.5    Cleris, L.6
  • 44
    • 38349193809 scopus 로고    scopus 로고
    • Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia
    • Wang L., Giannoudis A., Lane S., Williamson P., Pirmohamed M., Clark R.E. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 2008, 83:258-264.
    • (2008) Clin Pharmacol Ther , vol.83 , pp. 258-264
    • Wang, L.1    Giannoudis, A.2    Lane, S.3    Williamson, P.4    Pirmohamed, M.5    Clark, R.E.6
  • 45
    • 37049028176 scopus 로고    scopus 로고
    • Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity
    • White D.L., Saunders V.A., Dang P., Engler J., Venables A., Zrim S., et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 2007, 110:4064-4072.
    • (2007) Blood , vol.110 , pp. 4064-4072
    • White, D.L.1    Saunders, V.A.2    Dang, P.3    Engler, J.4    Venables, A.5    Zrim, S.6
  • 46
    • 77954936879 scopus 로고    scopus 로고
    • Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib
    • White D.L., Dang P., Engler J., Frede A., Zrim S., Osborn M., et al. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol 2010, 28:2761-2767.
    • (2010) J Clin Oncol , vol.28 , pp. 2761-2767
    • White, D.L.1    Dang, P.2    Engler, J.3    Frede, A.4    Zrim, S.5    Osborn, M.6
  • 47
    • 77950959714 scopus 로고    scopus 로고
    • Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity
    • Engler J.R., Frede A., Saunders V.A., Zannettino A.C., Hughes T.P., White D.L. Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity. Leukemia 2010, 24:765-770.
    • (2010) Leukemia , vol.24 , pp. 765-770
    • Engler, J.R.1    Frede, A.2    Saunders, V.A.3    Zannettino, A.C.4    Hughes, T.P.5    White, D.L.6
  • 48
    • 77957937825 scopus 로고    scopus 로고
    • The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34+ cells
    • [blood-2010-01-267013]
    • Engler J.R., Frede A., Saunders V., Zannettino A., White D.L., Hughes T.P. The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34+ cells. Blood 2010, [blood-2010-01-267013].
    • (2010) Blood
    • Engler, J.R.1    Frede, A.2    Saunders, V.3    Zannettino, A.4    White, D.L.5    Hughes, T.P.6
  • 49
    • 0033197989 scopus 로고    scopus 로고
    • Multidrug resistance protein expression in chronic myeloid leukemia: associations and significance
    • Giles F.J., Kantarjian H.M., Cortes J., Thomas D.A., Talpaz M., Manshouri T., et al. Multidrug resistance protein expression in chronic myeloid leukemia: associations and significance. Cancer 1999, 86:805-813.
    • (1999) Cancer , vol.86 , pp. 805-813
    • Giles, F.J.1    Kantarjian, H.M.2    Cortes, J.3    Thomas, D.A.4    Talpaz, M.5    Manshouri, T.6
  • 50
    • 0037443754 scopus 로고    scopus 로고
    • MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models
    • Mahon F.X., Belloc F., Lagarde V., Chollet C., Moreau-Gaudry F., Reiffers J., et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003, 101:2368-2373.
    • (2003) Blood , vol.101 , pp. 2368-2373
    • Mahon, F.X.1    Belloc, F.2    Lagarde, V.3    Chollet, C.4    Moreau-Gaudry, F.5    Reiffers, J.6
  • 51
    • 34250708413 scopus 로고    scopus 로고
    • Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels
    • [author reply 2-4]
    • Widmer N., Rumpold H., Untergasser G., Fayet A., Buclin T., Decosterd L.A. Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels. Leukemia 2007, 21:1561-1562. [author reply 2-4].
    • (2007) Leukemia , vol.21 , pp. 1561-1562
    • Widmer, N.1    Rumpold, H.2    Untergasser, G.3    Fayet, A.4    Buclin, T.5    Decosterd, L.A.6
  • 52
    • 20444482337 scopus 로고    scopus 로고
    • RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines
    • Rumpold H., Wolf A.M., Gruenewald K., Gastl G., Gunsilius E., Wolf D. RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines. Exp Hematol 2005, 33:767-775.
    • (2005) Exp Hematol , vol.33 , pp. 767-775
    • Rumpold, H.1    Wolf, A.M.2    Gruenewald, K.3    Gastl, G.4    Gunsilius, E.5    Wolf, D.6
  • 53
    • 67349280901 scopus 로고    scopus 로고
    • Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib
    • Hatziieremia S., Jordanides N.E., Holyoake T.L., Mountford J.C., Jorgensen H.G. Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib. Exp Hematol 2009, 37:692-700.
    • (2009) Exp Hematol , vol.37 , pp. 692-700
    • Hatziieremia, S.1    Jordanides, N.E.2    Holyoake, T.L.3    Mountford, J.C.4    Jorgensen, H.G.5
  • 54
    • 52649177063 scopus 로고    scopus 로고
    • Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia
    • Dulucq S., Bouchet S., Turcq B., Lippert E., Etienne G., Reiffers J., et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2008, 112:2024-2027.
    • (2008) Blood , vol.112 , pp. 2024-2027
    • Dulucq, S.1    Bouchet, S.2    Turcq, B.3    Lippert, E.4    Etienne, G.5    Reiffers, J.6
  • 55
    • 0030061157 scopus 로고    scopus 로고
    • Significance of cytogenetic clonal evolution in chronic myelogenous leukemia
    • Majlis A., Smith T., Talpaz M., O'Brien S., Rios M., Kantarjian H. Significance of cytogenetic clonal evolution in chronic myelogenous leukemia. J Clin Oncol 1996, 14:196-203.
    • (1996) J Clin Oncol , vol.14 , pp. 196-203
    • Majlis, A.1    Smith, T.2    Talpaz, M.3    O'Brien, S.4    Rios, M.5    Kantarjian, H.6
  • 57
    • 69249236962 scopus 로고    scopus 로고
    • The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia
    • Klemm L., Duy C., Iacobucci I., Kuchen S., von Levetzow G., Feldhahn N., et al. The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia. Cancer Cell 2009, 16:232-245.
    • (2009) Cancer Cell , vol.16 , pp. 232-245
    • Klemm, L.1    Duy, C.2    Iacobucci, I.3    Kuchen, S.4    von Levetzow, G.5    Feldhahn, N.6
  • 60
    • 77649222741 scopus 로고    scopus 로고
    • SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations
    • Nowak D., Ogawa S., Muschen M., Kato M., Kawamata N., Meixel A., et al. SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations. Blood 2010, 115:1049-1053.
    • (2010) Blood , vol.115 , pp. 1049-1053
    • Nowak, D.1    Ogawa, S.2    Muschen, M.3    Kato, M.4    Kawamata, N.5    Meixel, A.6
  • 61
    • 72849144434 scopus 로고    scopus 로고
    • Sequencing technologies [mdash] the next generation
    • Metzker M.L. Sequencing technologies [mdash] the next generation. Nat Rev Genet 2010, 11:31-46.
    • (2010) Nat Rev Genet , vol.11 , pp. 31-46
    • Metzker, M.L.1
  • 62
    • 0017653321 scopus 로고
    • Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage
    • Fialkow P.J., Jacobson R.J., Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med 1977, 63:125-130.
    • (1977) Am J Med , vol.63 , pp. 125-130
    • Fialkow, P.J.1    Jacobson, R.J.2    Papayannopoulou, T.3
  • 63
    • 13344262695 scopus 로고    scopus 로고
    • Normal and leukemic SCID-repopulating cells (SRC) coexist in the bone marrow and peripheral blood from CML patients in chronic phase, whereas leukemic SRC are detected in blast crisis
    • Sirard C., Lapidot T., Vormoor J., Cashman J., Doedens M., Murdoch B., et al. Normal and leukemic SCID-repopulating cells (SRC) coexist in the bone marrow and peripheral blood from CML patients in chronic phase, whereas leukemic SRC are detected in blast crisis. Blood 1996, 87:1539-1548.
    • (1996) Blood , vol.87 , pp. 1539-1548
    • Sirard, C.1    Lapidot, T.2    Vormoor, J.3    Cashman, J.4    Doedens, M.5    Murdoch, B.6
  • 64
    • 0033568250 scopus 로고    scopus 로고
    • Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia
    • Holyoake T., Jiang X., Eaves C., Eaves A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 1999, 94:2056-2064.
    • (1999) Blood , vol.94 , pp. 2056-2064
    • Holyoake, T.1    Jiang, X.2    Eaves, C.3    Eaves, A.4
  • 65
    • 0036090222 scopus 로고    scopus 로고
    • Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro
    • Graham S.M., Jorgensen H.G., Allan E., Pearson C., Alcorn M.J., Richmond L., et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002, 99:319-325.
    • (2002) Blood , vol.99 , pp. 319-325
    • Graham, S.M.1    Jorgensen, H.G.2    Allan, E.3    Pearson, C.4    Alcorn, M.J.5    Richmond, L.6
  • 67
    • 76249087423 scopus 로고    scopus 로고
    • TGF-[bgr]-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia
    • Naka K., Hoshii T., Muraguchi T., Tadokoro Y., Ooshio T., Kondo Y., et al. TGF-[bgr]-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature 2010, 463:676-680.
    • (2010) Nature , vol.463 , pp. 676-680
    • Naka, K.1    Hoshii, T.2    Muraguchi, T.3    Tadokoro, Y.4    Ooshio, T.5    Kondo, Y.6
  • 68
    • 64749091867 scopus 로고    scopus 로고
    • Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia
    • Zhao C., Chen A., Jamieson C.H., Fereshteh M., Abrahamsson A., Blum J., et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 2009, 458:776-779.
    • (2009) Nature , vol.458 , pp. 776-779
    • Zhao, C.1    Chen, A.2    Jamieson, C.H.3    Fereshteh, M.4    Abrahamsson, A.5    Blum, J.6
  • 69
    • 33749987744 scopus 로고    scopus 로고
    • Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph(+) CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon
    • Breccia M., Diverio D., Pane F., Nanni M., Russo E., Biondo F., et al. Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph(+) CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon. Leuk Res 2006, 30:1577-1579.
    • (2006) Leuk Res , vol.30 , pp. 1577-1579
    • Breccia, M.1    Diverio, D.2    Pane, F.3    Nanni, M.4    Russo, E.5    Biondo, F.6
  • 70
    • 33846023983 scopus 로고    scopus 로고
    • Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years
    • Rousselot P., Huguet F., Rea D., Legros L., Cayuela J.M., Maarek O., et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007, 109:58-60.
    • (2007) Blood , vol.109 , pp. 58-60
    • Rousselot, P.1    Huguet, F.2    Rea, D.3    Legros, L.4    Cayuela, J.M.5    Maarek, O.6
  • 72
    • 42549142280 scopus 로고    scopus 로고
    • Getting to the stem of chronic myeloid leukaemia
    • Savona M., Talpaz M. Getting to the stem of chronic myeloid leukaemia. Nat Rev Cancer 2008, 8:341-350.
    • (2008) Nat Rev Cancer , vol.8 , pp. 341-350
    • Savona, M.1    Talpaz, M.2
  • 73
    • 61849163272 scopus 로고    scopus 로고
    • Molecular biology of bcr-abl1-positive chronic myeloid leukemia
    • Quintas-Cardama A., Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 2009, 113:1619-1630.
    • (2009) Blood , vol.113 , pp. 1619-1630
    • Quintas-Cardama, A.1    Cortes, J.2
  • 74
    • 9144234689 scopus 로고    scopus 로고
    • Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia
    • Donato N.J., Wu J.Y., Stapley J., Lin H., Arlinghaus R., Aggarwal B.B., et al. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 2004, 64:672-677.
    • (2004) Cancer Res , vol.64 , pp. 672-677
    • Donato, N.J.1    Wu, J.Y.2    Stapley, J.3    Lin, H.4    Arlinghaus, R.5    Aggarwal, B.B.6
  • 75
    • 67651174451 scopus 로고    scopus 로고
    • Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors
    • Grosso S., Puissant A., Dufies M., Colosetti P., Jacquel A., Lebrigand K., et al. Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors. Mol Cancer Ther 2009, 8:1924-1933.
    • (2009) Mol Cancer Ther , vol.8 , pp. 1924-1933
    • Grosso, S.1    Puissant, A.2    Dufies, M.3    Colosetti, P.4    Jacquel, A.5    Lebrigand, K.6
  • 76
    • 0037438640 scopus 로고    scopus 로고
    • BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571
    • Donato N.J., Wu J.Y., Stapley J., Gallick G., Lin H., Arlinghaus R., et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003, 101:690-698.
    • (2003) Blood , vol.101 , pp. 690-698
    • Donato, N.J.1    Wu, J.Y.2    Stapley, J.3    Gallick, G.4    Lin, H.5    Arlinghaus, R.6
  • 77
    • 0029683347 scopus 로고    scopus 로고
    • Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells
    • Danhauser-Riedl S., Warmuth M., Druker B.J., Emmerich B., Hallek M. Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. Cancer Res 1996, 56:3589-3596.
    • (1996) Cancer Res , vol.56 , pp. 3589-3596
    • Danhauser-Riedl, S.1    Warmuth, M.2    Druker, B.J.3    Emmerich, B.4    Hallek, M.5
  • 79
    • 2442465000 scopus 로고    scopus 로고
    • Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia
    • Hu Y., Liu Y., Pelletier S., Buchdunger E., Warmuth M., Fabbro D., et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 2004, 36:453-461.
    • (2004) Nat Genet , vol.36 , pp. 453-461
    • Hu, Y.1    Liu, Y.2    Pelletier, S.3    Buchdunger, E.4    Warmuth, M.5    Fabbro, D.6
  • 80
    • 46849114097 scopus 로고    scopus 로고
    • Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase
    • Wu J., Meng F., Kong L.Y., Peng Z., Ying Y., Bornmann W.G., et al. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. J Natl Cancer Inst 2008, 100:926-939.
    • (2008) J Natl Cancer Inst , vol.100 , pp. 926-939
    • Wu, J.1    Meng, F.2    Kong, L.Y.3    Peng, Z.4    Ying, Y.5    Bornmann, W.G.6
  • 82
    • 33750303818 scopus 로고    scopus 로고
    • Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells
    • Fiskus W., Pranpat M., Balasis M., Bali P., Estrella V., Kumaraswamy S., et al. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. Clin Cancer Res 2006, 12:5869-5878.
    • (2006) Clin Cancer Res , vol.12 , pp. 5869-5878
    • Fiskus, W.1    Pranpat, M.2    Balasis, M.3    Bali, P.4    Estrella, V.5    Kumaraswamy, S.6
  • 83
    • 0033214222 scopus 로고    scopus 로고
    • ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia
    • Asimakopoulos F.A., Shteper P.J., Krichevsky S., Fibach E., Polliack A., Rachmilewitz E., et al. ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia. Blood 1999, 94:2452-2460.
    • (1999) Blood , vol.94 , pp. 2452-2460
    • Asimakopoulos, F.A.1    Shteper, P.J.2    Krichevsky, S.3    Fibach, E.4    Polliack, A.5    Rachmilewitz, E.6
  • 84
    • 77953725855 scopus 로고    scopus 로고
    • Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia
    • Kantarjian H., Shah N.P., Hochhaus A., Cortes J., Shah S., Ayala M., et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010, 362:2260-2270.
    • (2010) N Engl J Med , vol.362 , pp. 2260-2270
    • Kantarjian, H.1    Shah, N.P.2    Hochhaus, A.3    Cortes, J.4    Shah, S.5    Ayala, M.6
  • 86
    • 68949106066 scopus 로고    scopus 로고
    • Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance
    • Zhang W.W., Cortes J.E., Yao H., Zhang L., Reddy N.G., Jabbour E., et al. Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. J Clin Oncol 2009, 27:3642-3649.
    • (2009) J Clin Oncol , vol.27 , pp. 3642-3649
    • Zhang, W.W.1    Cortes, J.E.2    Yao, H.3    Zhang, L.4    Reddy, N.G.5    Jabbour, E.6
  • 87
    • 75649084233 scopus 로고    scopus 로고
    • A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib
    • McWeeney S.K., Pemberton L.C., Loriaux M.M., Vartanian K., Willis S.G., Yochum G., et al. A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. Blood 2010, 115:315-325.
    • (2010) Blood , vol.115 , pp. 315-325
    • McWeeney, S.K.1    Pemberton, L.C.2    Loriaux, M.M.3    Vartanian, K.4    Willis, S.G.5    Yochum, G.6
  • 88
    • 75749105885 scopus 로고    scopus 로고
    • Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study
    • Cortes J.E., Baccarani M., Guilhot F., Druker B.J., Branford S., Kim D.W., et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 2010, 28:424-430.
    • (2010) J Clin Oncol , vol.28 , pp. 424-430
    • Cortes, J.E.1    Baccarani, M.2    Guilhot, F.3    Druker, B.J.4    Branford, S.5    Kim, D.W.6
  • 89
    • 66549108340 scopus 로고    scopus 로고
    • Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study
    • Baccarani M., Rosti G., Castagnetti F., Haznedaroglu I., Porkka K., Abruzzese E., et al. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood 2009, 113:4497-4504.
    • (2009) Blood , vol.113 , pp. 4497-4504
    • Baccarani, M.1    Rosti, G.2    Castagnetti, F.3    Haznedaroglu, I.4    Porkka, K.5    Abruzzese, E.6
  • 90
    • 73349122639 scopus 로고    scopus 로고
    • Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet
    • Baccarani M., Cortes J., Pane F., Niederwieser D., Saglio G., Apperley J., et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009, 27:6041-6051.
    • (2009) J Clin Oncol , vol.27 , pp. 6041-6051
    • Baccarani, M.1    Cortes, J.2    Pane, F.3    Niederwieser, D.4    Saglio, G.5    Apperley, J.6
  • 91
    • 64049099666 scopus 로고    scopus 로고
    • Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy
    • Jabbour E., Kantarjian H.M., Jones D., Shan J., O'Brien S., Reddy N., et al. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 2009, 113:2154-2160.
    • (2009) Blood , vol.113 , pp. 2154-2160
    • Jabbour, E.1    Kantarjian, H.M.2    Jones, D.3    Shan, J.4    O'Brien, S.5    Reddy, N.6
  • 92
    • 19944428353 scopus 로고    scopus 로고
    • Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays
    • Lombardo L.J., Lee F.Y., Chen P., Norris D., Barrish J.C., Behnia K., et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004, 47:6658-6661.
    • (2004) J Med Chem , vol.47 , pp. 6658-6661
    • Lombardo, L.J.1    Lee, F.Y.2    Chen, P.3    Norris, D.4    Barrish, J.C.5    Behnia, K.6
  • 93
    • 37049014938 scopus 로고    scopus 로고
    • Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets
    • Rix U., Hantschel O., Durnberger G., Remsing Rix L.L., Planyavsky M., Fernbach N.V. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007, 110:4055-4063.
    • (2007) Blood , vol.110 , pp. 4055-4063
    • Rix, U.1    Hantschel, O.2    Durnberger, G.3    Remsing Rix, L.L.4    Planyavsky, M.5    Fernbach, N.V.6
  • 94
    • 70149105272 scopus 로고    scopus 로고
    • Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R)
    • Kantarjian H., Pasquini R., Levy V., Jootar S., Holowiecki J., Hamerschlak N., et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer 2009, 115:4136-4147.
    • (2009) Cancer , vol.115 , pp. 4136-4147
    • Kantarjian, H.1    Pasquini, R.2    Levy, V.3    Jootar, S.4    Holowiecki, J.5    Hamerschlak, N.6
  • 95
    • 45149087139 scopus 로고    scopus 로고
    • Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib
    • Hochhaus A., Baccarani M., Deininger M., Apperley J.F., Lipton J.H., Goldberg S.L., et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008, 22:1200-1206.
    • (2008) Leukemia , vol.22 , pp. 1200-1206
    • Hochhaus, A.1    Baccarani, M.2    Deininger, M.3    Apperley, J.F.4    Lipton, J.H.5    Goldberg, S.L.6
  • 96
    • 59549084574 scopus 로고    scopus 로고
    • The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up
    • Palandri F., Castagnetti F., Alimena G., Testoni N., Breccia M., Luatti S., et al. The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. Haematologica 2009, 94:205-212.
    • (2009) Haematologica , vol.94 , pp. 205-212
    • Palandri, F.1    Castagnetti, F.2    Alimena, G.3    Testoni, N.4    Breccia, M.5    Luatti, S.6
  • 97
    • 0037093092 scopus 로고    scopus 로고
    • Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study
    • Sawyers C.L., Hochhaus A., Feldman E., Goldman J.M., Miller C.B., Ottmann O.G., et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002, 99:3530-3539.
    • (2002) Blood , vol.99 , pp. 3530-3539
    • Sawyers, C.L.1    Hochhaus, A.2    Feldman, E.3    Goldman, J.M.4    Miller, C.B.5    Ottmann, O.G.6
  • 98
    • 70249141675 scopus 로고    scopus 로고
    • Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial
    • Apperley J.F., Cortes J.E., Kim D.W., Roy L., Roboz G.J., Rosti G., et al. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. J Clin Oncol 2009, 27:3472-3479.
    • (2009) J Clin Oncol , vol.27 , pp. 3472-3479
    • Apperley, J.F.1    Cortes, J.E.2    Kim, D.W.3    Roy, L.4    Roboz, G.J.5    Rosti, G.6
  • 99
    • 67650607999 scopus 로고    scopus 로고
    • Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up
    • Kantarjian H., Cortes J., Kim D.W., Dorlhiac-Llacer P., Pasquini R., DiPersio J., et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 2009, 113:6322-6329.
    • (2009) Blood , vol.113 , pp. 6322-6329
    • Kantarjian, H.1    Cortes, J.2    Kim, D.W.3    Dorlhiac-Llacer, P.4    Pasquini, R.5    DiPersio, J.6
  • 100
    • 57849159300 scopus 로고    scopus 로고
    • Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase
    • Cortes J., Kim D.W., Raffoux E., Martinelli G., Ritchie E., Roy L., et al. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 2008, 22:2176-2183.
    • (2008) Leukemia , vol.22 , pp. 2176-2183
    • Cortes, J.1    Kim, D.W.2    Raffoux, E.3    Martinelli, G.4    Ritchie, E.5    Roy, L.6
  • 101
    • 72149119119 scopus 로고    scopus 로고
    • Current role of stem cell transplantation in chronic myeloid leukaemia
    • Gratwohl A., Heim D. Current role of stem cell transplantation in chronic myeloid leukaemia. Best Pract Res Clin Haematol 2009, 22:431-443.
    • (2009) Best Pract Res Clin Haematol , vol.22 , pp. 431-443
    • Gratwohl, A.1    Heim, D.2
  • 103
    • 33745086350 scopus 로고    scopus 로고
    • Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
    • Kantarjian H., Giles F., Wunderle L., Bhalla K., O'Brien S., Wassmann B., et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006, 354:2542-2551.
    • (2006) N Engl J Med , vol.354 , pp. 2542-2551
    • Kantarjian, H.1    Giles, F.2    Wunderle, L.3    Bhalla, K.4    O'Brien, S.5    Wassmann, B.6
  • 104
    • 77955450607 scopus 로고    scopus 로고
    • Impact of prior therapy and suboptimal response to imatinib on the efficacy and safety of nilotinib among 1,422 patients with imatinib-resistant or --intolerant chronic myeloid leukemia (CML) in chronic phase (CP): sub-analyses of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study
    • Nicolini F.E., Kim D.-W., Ceglarek B., Turkina A., Alimena G., Al-Ali H.K., et al. Impact of prior therapy and suboptimal response to imatinib on the efficacy and safety of nilotinib among 1,422 patients with imatinib-resistant or --intolerant chronic myeloid leukemia (CML) in chronic phase (CP): sub-analyses of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study. ASH Annual Meeting Abstracts 2009, 114:2201-
    • (2009) ASH Annual Meeting Abstracts , vol.114
    • Nicolini, F.E.1    Kim, D.-W.2    Ceglarek, B.3    Turkina, A.4    Alimena, G.5    Al-Ali, H.K.6
  • 105
    • 36348968931 scopus 로고    scopus 로고
    • Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
    • Kantarjian H.M., Giles F., Gattermann N., Bhalla K., Alimena G., Palandri F., et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007, 110:3540-3546.
    • (2007) Blood , vol.110 , pp. 3540-3546
    • Kantarjian, H.M.1    Giles, F.2    Gattermann, N.3    Bhalla, K.4    Alimena, G.5    Palandri, F.6
  • 106
    • 79551516839 scopus 로고    scopus 로고
    • Response and outcomes to nilotinib at 24months in imatinib-resistant chronic myeloid leukemia patients in chronic phase (CML-CP) and accelerated phase (CML-AP) with and without BCR-ABL mutations
    • Radich J.P., Martinelli G., Hochhaus A., Gottardi E., Soverini S., Branford S., et al. Response and outcomes to nilotinib at 24months in imatinib-resistant chronic myeloid leukemia patients in chronic phase (CML-CP) and accelerated phase (CML-AP) with and without BCR-ABL mutations. ASH Annual Meeting Abstracts 2009, 114:1130-
    • (2009) ASH Annual Meeting Abstracts , vol.114
    • Radich, J.P.1    Martinelli, G.2    Hochhaus, A.3    Gottardi, E.4    Soverini, S.5    Branford, S.6
  • 108
    • 65649098667 scopus 로고    scopus 로고
    • Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 Study
    • le Coutre P.D., Giles F., Hochhaus A., Apperley J.F., Ossenkoppele G., Haque A., et al. Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 Study. ASH Annual Meeting Abstracts 2008, 112:3229-
    • (2008) ASH Annual Meeting Abstracts , vol.112
    • le Coutre, P.D.1    Giles, F.2    Hochhaus, A.3    Apperley, J.F.4    Ossenkoppele, G.5    Haque, A.6
  • 110
    • 70349245253 scopus 로고    scopus 로고
    • Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations
    • Jabbour E., Jones D., Kantarjian H.M., O'Brien S., Tam C., Koller C., et al. Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood 2009, 114:2037-2043.
    • (2009) Blood , vol.114 , pp. 2037-2043
    • Jabbour, E.1    Jones, D.2    Kantarjian, H.M.3    O'Brien, S.4    Tam, C.5    Koller, C.6
  • 111
    • 70249105789 scopus 로고    scopus 로고
    • Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase
    • Hughes T., Saglio G., Branford S., Soverini S., Kim D.W., Muller M.C., et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol 2009, 27:4204-4210.
    • (2009) J Clin Oncol , vol.27 , pp. 4204-4210
    • Hughes, T.1    Saglio, G.2    Branford, S.3    Soverini, S.4    Kim, D.W.5    Muller, M.C.6
  • 112
    • 47249123747 scopus 로고    scopus 로고
    • Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy
    • Jabbour E., Kantarjian H., Jones D., Breeden M., Garcia-Manero G., O'Brien S., et al. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 2008, 112:53-55.
    • (2008) Blood , vol.112 , pp. 53-55
    • Jabbour, E.1    Kantarjian, H.2    Jones, D.3    Breeden, M.4    Garcia-Manero, G.5    O'Brien, S.6
  • 113
    • 0035829463 scopus 로고    scopus 로고
    • Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity
    • Boschelli D.H., Ye F., Wang Y.D., Dutia M., Johnson S.L., Wu B., et al. Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity. J Med Chem 2001, 44:3965-3977.
    • (2001) J Med Chem , vol.44 , pp. 3965-3977
    • Boschelli, D.H.1    Ye, F.2    Wang, Y.D.3    Dutia, M.4    Johnson, S.L.5    Wu, B.6
  • 114
    • 0037439689 scopus 로고    scopus 로고
    • SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice
    • Golas J.M., Arndt K., Etienne C., Lucas J., Nardin D., Gibbons J., et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 2003, 63:375-381.
    • (2003) Cancer Res , vol.63 , pp. 375-381
    • Golas, J.M.1    Arndt, K.2    Etienne, C.3    Lucas, J.4    Nardin, D.5    Gibbons, J.6
  • 117
    • 31344435118 scopus 로고    scopus 로고
    • Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors
    • Asaki T., Sugiyama Y., Hamamoto T., Higashioka M., Umehara M., Naito H., et al. Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors. Bioorg Med Chem Lett 2006, 16:1421-1425.
    • (2006) Bioorg Med Chem Lett , vol.16 , pp. 1421-1425
    • Asaki, T.1    Sugiyama, Y.2    Hamamoto, T.3    Higashioka, M.4    Umehara, M.5    Naito, H.6
  • 118
    • 28444479480 scopus 로고    scopus 로고
    • NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia
    • Kimura S., Naito H., Segawa H., Kuroda J., Yuasa T., Sato K., et al. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 2005, 106:3948-3954.
    • (2005) Blood , vol.106 , pp. 3948-3954
    • Kimura, S.1    Naito, H.2    Segawa, H.3    Kuroda, J.4    Yuasa, T.5    Sato, K.6
  • 119
    • 77952840150 scopus 로고    scopus 로고
    • Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance
    • Kantarjian H., Coutre Pl, Cortes J., Pinilla-Ibarz J., Nagler A., Hochhaus A., et al. Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance. Cancer 2010, 116:2665-2672.
    • (2010) Cancer , vol.116 , pp. 2665-2672
    • Kantarjian, H.1    Coutre, P.2    Cortes, J.3    Pinilla-Ibarz, J.4    Nagler, A.5    Hochhaus, A.6
  • 120
    • 4644368478 scopus 로고    scopus 로고
    • Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML
    • O'Hare T., Pollock R., Stoffregen E.P., Keats J.A., Abdullah O.M., Moseson E.M., et al. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood 2004, 104:2532-2539.
    • (2004) Blood , vol.104 , pp. 2532-2539
    • O'Hare, T.1    Pollock, R.2    Stoffregen, E.P.3    Keats, J.A.4    Abdullah, O.M.5    Moseson, E.M.6
  • 121
    • 70350507997 scopus 로고    scopus 로고
    • AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance
    • O'Hare T., Shakespeare W.C., Zhu X., Eide C.A., Rivera V.M., Wang F., et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009, 16:401-412.
    • (2009) Cancer Cell , vol.16 , pp. 401-412
    • O'Hare, T.1    Shakespeare, W.C.2    Zhu, X.3    Eide, C.A.4    Rivera, V.M.5    Wang, F.6
  • 122
    • 77949674913 scopus 로고    scopus 로고
    • A phase 1 trial of oral AP24534 in patients with refractory chronic myeloid leukemia and other hematologic malignancies: first results of safety and clinical activity against T315I and resistant mutations
    • Cortes J., Talpaz M., Deininger M., Shah N., Flinn I.W., Mauro M.J., et al. A phase 1 trial of oral AP24534 in patients with refractory chronic myeloid leukemia and other hematologic malignancies: first results of safety and clinical activity against T315I and resistant mutations. ASH Annual Meeting Abstracts 2009, 114:643-
    • (2009) ASH Annual Meeting Abstracts , vol.114
    • Cortes, J.1    Talpaz, M.2    Deininger, M.3    Shah, N.4    Flinn, I.W.5    Mauro, M.J.6
  • 123
    • 77950949478 scopus 로고    scopus 로고
    • Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias
    • Moore A.S., Blagg J., Linardopoulos S., Pearson A.D. Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias. Leukemia 2010, 24:671-678.
    • (2010) Leukemia , vol.24 , pp. 671-678
    • Moore, A.S.1    Blagg, J.2    Linardopoulos, S.3    Pearson, A.D.4
  • 124
    • 77950919574 scopus 로고    scopus 로고
    • Danusertib hydrochloride (PHA-739358), a multi-kinase aurora inhibitor, elicits clinical benefit in advanced chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia
    • Cortes-Franco J., Dombret H., Schafhausen P., Brummendorf T.H., Boissel N., Latini F., et al. Danusertib hydrochloride (PHA-739358), a multi-kinase aurora inhibitor, elicits clinical benefit in advanced chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia. ASH Annual Meeting Abstracts 2009, 114:864-
    • (2009) ASH Annual Meeting Abstracts , vol.114
    • Cortes-Franco, J.1    Dombret, H.2    Schafhausen, P.3    Brummendorf, T.H.4    Boissel, N.5    Latini, F.6
  • 125
    • 60549088370 scopus 로고    scopus 로고
    • Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity†
    • Howard S., Berdini V., Boulstridge J.A., Carr M.G., Cross D.M., Curry J., et al. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity†. J Med Chem 2008, 52:379-388.
    • (2008) J Med Chem , vol.52 , pp. 379-388
    • Howard, S.1    Berdini, V.2    Boulstridge, J.A.3    Carr, M.G.4    Cross, D.M.5    Curry, J.6
  • 126
    • 77957201111 scopus 로고    scopus 로고
    • Activity of the multi-targeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL positive leukemic cells
    • [blood-2009-03-211466]
    • Tanaka R., Squires M.S., Kimura S., Yokota A., Nagao R., Yamauchi T., et al. Activity of the multi-targeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL positive leukemic cells. Blood 2010, [blood-2009-03-211466].
    • (2010) Blood
    • Tanaka, R.1    Squires, M.S.2    Kimura, S.3    Yokota, A.4    Nagao, R.5    Yamauchi, T.6
  • 127
    • 64349094896 scopus 로고    scopus 로고
    • A phase I trial of AT9283, a multitargeted kinase inhibitor, in patients with refractory hematological malignancies
    • Ravandi F., Foran J., Verstovsek S., Cortes J., Wierda W., Boone P., et al. A phase I trial of AT9283, a multitargeted kinase inhibitor, in patients with refractory hematological malignancies. ASH Annual Meeting Abstracts 2007, 110:904-
    • (2007) ASH Annual Meeting Abstracts , vol.110
    • Ravandi, F.1    Foran, J.2    Verstovsek, S.3    Cortes, J.4    Wierda, W.5    Boone, P.6
  • 128
    • 72249090201 scopus 로고    scopus 로고
    • Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009
    • Quintás-Cardama A., Kantarjian H., Cortes J. Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. Cancer 2009, 115:5382-5393.
    • (2009) Cancer , vol.115 , pp. 5382-5393
    • Quintás-Cardama, A.1    Kantarjian, H.2    Cortes, J.3
  • 129
    • 77957089790 scopus 로고    scopus 로고
    • Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in chronic myeloid leukemia (CML) patients who are resistant or intolerant to two or more tyrosine kinase inhibitors - results of a multicenter phase 2/3 study
    • Cortes-Franco J., Raghunadharao D., Parikh P., Wetzler M., Lipton J.H., Jones D., et al. Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in chronic myeloid leukemia (CML) patients who are resistant or intolerant to two or more tyrosine kinase inhibitors - results of a multicenter phase 2/3 study. ASH Annual Meeting Abstracts 2009, 114:861-
    • (2009) ASH Annual Meeting Abstracts , vol.114
    • Cortes-Franco, J.1    Raghunadharao, D.2    Parikh, P.3    Wetzler, M.4    Lipton, J.H.5    Jones, D.6
  • 130
    • 77950394312 scopus 로고    scopus 로고
    • Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients who harbor the Bcr-Abl T315I mutation-results of an ongoing multicenter phase 2/3 study
    • Cortes-Franco J., Khoury H.J., Nicolini F.E., Corm S., Lipton J.H., Jones D., et al. Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients who harbor the Bcr-Abl T315I mutation-results of an ongoing multicenter phase 2/3 study. ASH Annual Meeting Abstracts 2009, 114:644-
    • (2009) ASH Annual Meeting Abstracts , vol.114
    • Cortes-Franco, J.1    Khoury, H.J.2    Nicolini, F.E.3    Corm, S.4    Lipton, J.H.5    Jones, D.6
  • 131
    • 43749121647 scopus 로고    scopus 로고
    • DCC-2036: a novel switch pocket inhibitor of ABL tyrosine kinase with therapeutic efficacy against BCR-ABL T315I in vitro and in a CML mouse model
    • Van Etten R.A., Chan W.W., Zaleskas V.M., Evangelista P., Lazarides K., Peng C., et al. DCC-2036: a novel switch pocket inhibitor of ABL tyrosine kinase with therapeutic efficacy against BCR-ABL T315I in vitro and in a CML mouse model. ASH Annual Meeting Abstracts 2007, 110:463-
    • (2007) ASH Annual Meeting Abstracts , vol.110
    • Van Etten, R.A.1    Chan, W.W.2    Zaleskas, V.M.3    Evangelista, P.4    Lazarides, K.5    Peng, C.6
  • 132
    • 68949087742 scopus 로고    scopus 로고
    • Switch pocket inhibitors of the ABL tyrosine kinase: distinct kinome inhibition profiles and in vivo efficacy in mouse models of CML and B-lymphoblastic leukemia induced by BCR-ABL T315I
    • Van Etten R.A., Chan W.W., Zaleskas V.M., Walz C., Evangelista P., Lazarides K., et al. Switch pocket inhibitors of the ABL tyrosine kinase: distinct kinome inhibition profiles and in vivo efficacy in mouse models of CML and B-lymphoblastic leukemia induced by BCR-ABL T315I. ASH Annual Meeting Abstracts 2008, 112:576-
    • (2008) ASH Annual Meeting Abstracts , vol.112
    • Van Etten, R.A.1    Chan, W.W.2    Zaleskas, V.M.3    Walz, C.4    Evangelista, P.5    Lazarides, K.6
  • 133
    • 0028813711 scopus 로고
    • Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy
    • Kantarjian H.M., Smith T.L., O'Brien S., Beran M., Pierce S., Talpaz M., et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann Intern Med 1995, 122:254-261.
    • (1995) Ann Intern Med , vol.122 , pp. 254-261
    • Kantarjian, H.M.1    Smith, T.L.2    O'Brien, S.3    Beran, M.4    Pierce, S.5    Talpaz, M.6
  • 134
    • 77956035133 scopus 로고    scopus 로고
    • The response to imatinib and interferon-{alpha} is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase
    • Palandri F., Castagnetti F., Iacobucci I., Martinelli G., Amabile M., Gugliotta G., et al. The response to imatinib and interferon-{alpha} is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. Haematologica 2010, 95:1415-1419.
    • (2010) Haematologica , vol.95 , pp. 1415-1419
    • Palandri, F.1    Castagnetti, F.2    Iacobucci, I.3    Martinelli, G.4    Amabile, M.5    Gugliotta, G.6
  • 135
    • 77950496740 scopus 로고    scopus 로고
    • Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia
    • Burchert A., Muller M.C., Kostrewa P., Erben P., Bostel T., Liebler S., et al. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J Clin Oncol 2010, 28:1429-1435.
    • (2010) J Clin Oncol , vol.28 , pp. 1429-1435
    • Burchert, A.1    Muller, M.C.2    Kostrewa, P.3    Erben, P.4    Bostel, T.5    Liebler, S.6
  • 137
    • 41349083969 scopus 로고    scopus 로고
    • Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia
    • le Coutre P., Ottmann O.G., Giles F., Kim D.W., Cortes J., Gattermann N., et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 2008, 111:1834-1839.
    • (2008) Blood , vol.111 , pp. 1834-1839
    • le Coutre, P.1    Ottmann, O.G.2    Giles, F.3    Kim, D.W.4    Cortes, J.5    Gattermann, N.6
  • 139
    • 67349137674 scopus 로고    scopus 로고
    • A phase I dose escalation study of kw-2449, An Oral Multi-Kinase Inhibitor against FLT3, Abl, FGFR1 and Aurora in Patients with Relapsed/Refractory AML, ALL and MDS or Resistant/Intolerant CML
    • Cortes J., Roboz G.J., Kantarjian H.M., Feldman E.J., Karp J.E., Pratz K.W., et al. A phase I dose escalation study of kw-2449, An Oral Multi-Kinase Inhibitor against FLT3, Abl, FGFR1 and Aurora in Patients with Relapsed/Refractory AML, ALL and MDS or Resistant/Intolerant CML. ASH Annual Meeting Abstracts 2008, 112:2967-
    • (2008) ASH Annual Meeting Abstracts , vol.112
    • Cortes, J.1    Roboz, G.J.2    Kantarjian, H.M.3    Feldman, E.J.4    Karp, J.E.5    Pratz, K.W.6
  • 140
    • 33846240316 scopus 로고    scopus 로고
    • MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation
    • Giles F.J., Cortes J., Jones D., Bergstrom D., Kantarjian H., Freedman S.J. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2007, 109:500-502.
    • (2007) Blood , vol.109 , pp. 500-502
    • Giles, F.J.1    Cortes, J.2    Jones, D.3    Bergstrom, D.4    Kantarjian, H.5    Freedman, S.J.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.